ImmunoGen Inc (NASDAQ: IMGN). Extremely significant positive changes in investment behavior have recently occurred: positive upside/downside volume developed, and the stock’s recent price rise disrupted its longer term downtrend.
ImmunoGen Inc (NASDAQ: IMGN). Notable positive changes in fundamentals have recently occurred: significant quarterly sales acceleration occurred, and the consensus estimate for December, 2023 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
IMGN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to be a major Value Builder.
ImmunoGen has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. ImmunoGen has a very low Appreciation Score of 7 but a very high Power Rating of 98, producing the Neutral Value Trend Rating.
Recent Price Action
ImmunoGen Inc (NASDAQ: IMGN) stock declined slightly by -0.5% on 1/3/24. The stock closed at $29.50. NORMAL trading volume accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -0.7% during the last week.
Be the first to comment